# Gallant Pet

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gallant-pet

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.gallant.com
- Total disclosed funding: $51M
- Latest round: Series B (Jun 27, 2025)
- Investors on record: 5

## About

Founded in 2018 and based in California, US, Gallant Pet, Inc., trading under the name Gallant Therapeutics, is a company that provides healthcare solutions using stem cell therapy for dogs and cats. In June 2025, Gallant Pet, Inc. raised USD 18 million in series B funding led by returning investor Digitalis Ventures, with participation from other returning investors BOLD Capital Partners and Hill Creek Partners. New investor NovaQuest Capital Management also participated in the round. Gallant's offerings includes an off-the-shelf stem cell platform that helps in mitigating symptoms and treating the causes of pet diseases. The firm helps its customers with stem cell collection, stem cell banking, and regenerative treatments for pets. The company will use the June 2025 funding for product development.

## Funding rounds

- Series B, Jun 27, 2025, $10M — NovaQuest Capital Management, BOLD Capital Partners, Digitalis Ventures, Hill Creek Partners
- Series A, Jan 8, 2024, $15M — BOLD Capital Partners, Digitalis Ventures, Hill Creek Partners
- Series A, Dec 15, 2022, $25M — Alumni Ventures Group

## Investors

- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series A
- BOLD Capital Partners (https://capitalatlas.ai/funds/bold-capital-partners) — Series A, Series B
- Digitalis Ventures (https://capitalatlas.ai/funds/digitalis-ventures) — Series A, Series B
- Hill Creek Partners — Series A, Series B
- NovaQuest Capital Management (https://capitalatlas.ai/funds/novaquest-capital-management) — Series B